Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13661MR)

This product GTTS-WQ13661MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13661MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10341MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ10316MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LJM716
GTTS-WQ1730MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ5901MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ5161MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ13502MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ14571MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ13694MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW